Particulate antigen assemblies in the nanometer range and DNA plasmids are particularly interesting for designing vaccines. We hypothesised that a combination of these approaches could result in a new delivery method of gp160 envelope HIV-1 vaccine which could combine the potency of virus-like particles (VLPs) and the simplicity of use of DNA vaccines. Characterisation of lentivirus-like particles (lentiVLPs) by western blot, dynamic light scattering and electron microscopy revealed that their protein pattern, size and structure make them promising candidates for HIV-1 vaccines. Although all particles were similar with regard to size and distribution, they clearly differed in p24 capsid protein content suggesting that Rev may be required for particle maturation and Gag processing. In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combination of gp160 and VSV-G envelopes did not influence the magnitude of the immune response but the combination of lentiVLPs with Alum adjuvant resulted in a more potent response. Interestingly, the strongest immune response was obtained when plasmids encoding lentiVLPs were co-delivered to mice muscles by electrotransfer, suggesting that lentiVLPs were efficiently produced in vivo or the packaging genes mediate an adjuvant effect. DNA electrotransfer of plasmids encoding lentivirus-like particles offers many advantages and appears therefore as a promising delivery method of HIV-1 vaccines.
Introduction
The Human Immunodeficiency Virus (HIV) was discovered more than 25 years ago. Intensive study of the virus has led to the development of antiviral treatments which considerably improve the life expectancy of infected patients. However, no curative drug has been discovered and the quest for an efficient HIV vaccine continues. For other viruses, attenuated live virus vaccines have been shown to induce a broad immune response. However, the risk of attenuated viruses causing active disease, in particular in immunocompromised patients, makes them unattractive vaccine candidates for HIV. A variety of alternate approaches is therefore being investigated [1] . gp160 envelope glycoprotein is known to be an important target for HIV-1 vaccines. Indeed, it contains several epitopes and is subject to both humoral and cellular immune responses [2] .
Particulate antigen assemblies in the nanometre range are particularly interesting for vaccine design. Their size, shape and surface molecule organization, mimicking key features of pathogens, appear critical for the development of immune responses (for review, [3] ). VLPs are selfassembling, non-replicating, non-pathogenic and genomeless particles that are similar in size and conformation to intact infectious virions [4] . They present two interesting characteristics favouring their uptake and their processing by the immune system : (i) their repetitive antigenic structure efficiently stimulates the immune system as seen with native viruses but without infectivity risks; (ii) and their size (from 20 to 200 nm in diameter) allows for better interaction with antigen-presenting cells compared to soluble proteins [3] . LentiVLPs must contain Gag for particle assembly, budding, and release from the host cell [5, 6] . It has been shown that purified lentiVLPs are able to induce an effective HIV-1 antibody response with neutralization activity [7] and to activate multiple types of immune cells [8] . However, their manufacture is rather complex and their production and purification are challenging [9] . They have been produced in different expression systems and the optimization of in vitro production methods is a current challenge [10] .
Parallel to the development of VLPs, there is a growing interest in DNA vaccines. Combined with efficient delivery methods such as electrotransfer or gene gun, DNA vaccines are able to generate immune responses targeting various diseases such as cancer or HIV [11, 12] . DNA electrotransfer is one of the most efficient non-viral delivery methods. It consists of the application of high voltage pulses through electrodes placed around the site of plasmid injection [13, 14] . The pulses provoke destabilization of the cell membrane and, as DNA is negatively charged, they promote its electrophoretic migration. The use of DNA as a vaccine presents many advantages: (i) DNA vaccines can be engineered using generic methods which result in simpler GMP (Good Manufacturing Practice) production; (ii) storage and shipping are simplified as plasmid DNA is very stable; (iii) and antigen can be efficiently presented by both MHC class I and class II molecules. However, although DNA vaccines have proven their efficiency in a wide variety of animal models, the immune responses in human have not been as great as anticipated from the preclinical studies [12] . It is therefore critical to develop new methods to further improve the immunogenicity of such vaccines.
Here, we aimed at characterizing and developing efficient delivery methods for gp160 envelope vaccines. The delivery of such vaccines by either lentiVLPs or DNA electrotransfer was first evaluated. We then hypothesised that a combination of these approaches could result in a new delivery method of HIV-1 vaccine combining the potency of VLPs and the simplicity of use of DNA vaccines. Strong immune responses were observed in mice, particularly when the combination method was used.
Materials and methods

Plasmids
The pRRLSIN.cPPT.PKG-GFP.WPRE (transfer), pMDLg/pRRE (packaging), pRSV-Rev (Rev) and pMD2.g (VSV-G Env) plasmids were purchased from Addgene (Fargo, ND). pcDNA3.1(−)-96ZM-gp160CD5 (gp160 Env) plasmid encodes the HIV type-1 (HIV-1) envelope glycoprotein. Plasmids were prepared using Qiagen Endofree Plasmid Maxi or Giga Kit according to the manufacturer's protocol. The quality of the resulting plasmids was assessed by the ratio of light absorption (260 nm/280 nm) and by 1% agarose gel electrophoresis. Light absorption at 260 nm was used to determine DNA concentration. All plasmid dilutions were done in 0.9% NaCl. Plasmids were stored at −20°C before use.
LentiVLP and LV production
For lentiVLP production, 30 × 10 6 293 T cells, grown in complete DMEM medium (with 10% FBS, 2 mM L-Glutamine, 100 μg/ml streptomycin, and 100U/ml penicillin), were transiently transfected with lipofectamine 2000 following manufacturer's instructions (Invitrogen, UK). Packaging, gp160 Env and VSV-G Env plasmids were used at specific molar ratios in order to produce gp160, gp160/VSV-G and VSV-G lentiVLPs. LentiVLP-Rev were produced in the same way using, in addition, the Rev plasmid (Table 1) . Medium was replaced 24 h after transfection and the supernatants were collected at days 2, 3 and 4 post-transfection. Debris was removed by low-speed centrifugation and by filtration through a 0.45 μm filter. Filtered supernatants were then ultracentrifuged (50,000 g, 2.5 h, 4°C) through 20% sucrose, and lentiVLPs were resuspended in 100 μL PBS and stored at −80°C. A similar method was applied for production of lentiviruses (LVs) using packaging, Rev, transfer, gp160 Env and/or VSV-G Env plasmids in order to produce gp160, gp160/VSV-G and VSV-G LVs respectively (Table 1) . Micro BCA procedure was used to assay total protein content of each preparation (Pierce, Thermo Scientific, UK).
p24 assay
HIV-1 p24 CA antigen capture assay kit was purchased from the National Cancer Institute (NIH, USA). Briefly, 10-fold serial dilutions (10 3 to 10 5 ) of the Triton X-100-disrupted particles were captured with mouse anti-HIV-1 p24 monoclonal antibodies. Captured protein was detected by rabbit anti-HIV-1 p24 and goat anti-rabbit IgG HRP as primary and secondary antibodies respectively. HPLC-purified p24 was used as a standard. This assay was performed in duplicate.
Western blot assays
LentiVLPs and LVs (15 μL of 1/10 diluted preparations) were loaded onto 4-12% NuPAGE Bis-Tris gels and electrophoresis was performed with MES SDS buffer following the manufacturer's instructions (Invitrogen, UK). Proteins were then transferred to Hybond-ECL membrane (Amersham, GE Healthcare, UK). Mouse monoclonal antibodies to HIV-1 gp160/gp120, HIV-1 p24 (Centre for AIDS Reagents, NIBSC, UK) and to VSV-G TAG (Abcam, Cambridge, UK), all diluted 1/5000, were used as primary antibodies and polyclonal goat anti-mouse immunoglobulin labelled with HRP (Dako, UK), diluted 1/2000, as secondary antibody.
Dynamic light scattering
Samples were diluted 100-fold in PBS and filtered through a 0.45 μm filter. Particle size distribution was determined in triplicate by means of dynamic light scattering (DLS) using a NanoSizer ZS (Malvern Instruments, UK) and data were analyzed using the Dispersion Technology Software 5.00.
Electron microscopy
Samples were absorbed to 400 mesh formvar coated EM grids that were glow discharged for 2 min, then washed in distilled water, negative contrasted with 1% uranyl acetate and dried. Grids were examined in a FEI Tecnai electron microscope and digital images were acquired using a Megaview III CCD camera.
Mice immunization
BALB/c male mice were obtained from Harlan laboratories (UK) and housed in a minimal disease facility with food and water ad libitum. Mice were between 9 and 10-week-old at the beginning of the experiment and received one priming and one boost, three weeks later, which consisted either of intramuscular plasmid electrotransfer or intradermal injection of lentiVLPs.
Prior to the intramuscular injection mice were anaesthetised via an intra-peritoneal injection of fentanyl/fluanisone and midazolam (Hypnorm, Janssen Animal Health, High Wycombe, UK and Hypnovel, Roche, Welwyn Garden City, UK, respectively). Tibialis anterior (TA) muscles were injected using a 27-gauge needle with 10 U (25 μL at 0.4 U/μL) of bovine hyaluronidase (Sigma, Poole, UK) [15] . Two hours post-hyaluronidase injection, 25 μg plasmid DNA mix (1 mg/ml) in PBS was injected percutaneously in the TA muscles. An electrical field Table 1 Molar ratio used for particle production.
Lentiviruses
Lentivirus Like particles Lentivirus Like particles -Rev
was applied to the muscle immediately following plasmid injection. The injection of plasmid DNA and the electrotransfer of plasmid DNA were carried out under isoflurane inhalation anaesthesia. The injected leg was held steady and ten 20 ms pulses of 175 V/cm were delivered at a 1 Hz frequency using the Elgen 1000 electroporation device (Inovio, San Diego, CA) and through plate electrodes applied to the medial and lateral sides of the lower hind limb with reasonable pressure to maintain contact with the skin surface. Electrode jelly was used on the electrode plates to ensure good electrical contact (Modul diagram s.r.l., Castel Bolognese, Italy). The DNA mix was made of packaging, gp160 Env and VSV-G Env plasmids at 1:1:0, 1:0.5:0.5 or 0:1:0 molar ratios for DNA gp160 lentiVLP, DNA gp160/VSV-G lentiVLP and DNA gp160 injections, respectively. For the immunization with lentiVLPs, 25 μg gp160 lentiVLPs or gp160/VSV-G lentiVLPs were diluted in 50 μl of PBS or in 25 μl PBS and then combined with 25 μl with Imject® Alum following the manufacturer's protocol (Pierce, Thermo Scientific, UK).
Mice were injected intradermally with two volumes of 50 μl in the back skin.
gp160 expression after DNA electrotransfer
The levels of gp160 expression were measured two days after plasmid electrotransfer. Mice were sacrificed and their TA muscles were sampled and homogenized in 0.3 ml of cell culture lysis reagent solution (CCLR, Promega Benelux) containing a protease inhibitor cocktail (Roche, Mannheim, Germany) using disposable pestles and motor mixer (VWR, Belgium). After centrifugation at 12,000 g for 10 min at 4°C, we assessed the gp160 content of each sample by a sandwich ELISA assay. 96-well plates were coated at 37°C overnight with 50 μl/well of 6 μg/ml human monoclonal antibody 4E10 directed to gp41 diluted in sodium carbonate-bicarbonate buffer pH 9.4. After washing with PBS-0.05% Tween 20, plates were blocked with 300 μl/well of PBS-0.05% Tween 20-0.5% dry milk for 1 h at 37°C. Washed plates were then incubated for 1 h at 37°C with 50 μl/well of the samples diluted two times in PBS-0.05% Tween 20-2.5% dry milk. Plates were then washed and incubated for 1 h at 37°C with murine monoclonal IgG1 to HIV-1 gp160/gp120 (ARP301) diluted 200 times in PBS-0.05% Tween 20-2.5% dry milk (50 μl/well). LO-MG1-13 (IMEX, UCL, Brussels, Belgium) directed to mouse Ig1 labelled with peroxidase and diluted 1/500 was used as secondary antibody and incubated for 1 h at 37°C. TMB (Thermo Scientific, UK) was used following the manufacturer's instructions and plates were read at 450 nm.
Immune response analysis
Two weeks after delivery of the boost, blood samples were collected and sera were separated by centrifugation at 3300 g for 10 min at 4°C. A sandwich ELISA assay was developed in order to assess the immune response directed to gp160 envelope. 96-well plates were coated at 37°C overnight with 50 μl/well of 6 μg/ml human monoclonal antibody 4E10 directed to gp41 diluted in sodium carbonate-bicarbonate buffer pH 9.4. After washing with PBS-0.05% Tween 20, plates were blocked with 300 μl/well of PBS-0.05% Tween 20-0.5% dry milk for 1 h at 37°C. Washed plates were then incubated for 1 h at 37°C with 50 μl/well of gp160-containing supernatant that was collected 48 h after transfection of 293 T cells with pcDNA3.1(−)-96ZM-gp160CD5, centrifuged and filtered through 0.45 μm membrane. Plates were then washed and incubated for 1 h at 37°C with serial 2-fold dilutions of sera samples diluted in PBS-0.05% Tween 20-2.5% dry milk (50 μl/well). 50 μl/well of goat anti-mouse IgG labelled with biotin (Dako) diluted 1/2000 was used as secondary antibody and incubated for 1 h at 37°C and each well was then washed and incubated with streptavidin/HRP for 1 h. TMB (Thermo Scientific, UK) was used following the manufacturer's instructions and plates were read at 450 nm. Titres of serum antibodies were defined as the dilution giving an optical density equal to the limit of quantification (LQ =mean + 10× standard deviation of blank values). Isotypes of anti-gp160 antibodies (IgG1, IgG2a, IgG2b) were determined in duplicate on pooled sera using appropriate secondary antibodies (LO-MG1-13, LO-MG2A-9 and LO-MG2B-2 labelled with peroxidase, IMEX, UCL, Brussels, Belgium) as previously described [14] . To compare the proportion of gp160-specific antibodies with a particular isotype, results were documented as the percent of the titre attributed to each isotype, i.e. (titre of each individual isotype / sum of individual titres) ×100. Since the sensitivity of each isotypespecific antibody may be different, this calculation provides the means to compare relative amounts of each isotype but does not reflect absolute antibody quantities [16] .
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 for Windows.
Results and discussion
Protein patterns in lentivirus-like particles and lentiviral vectors
LentiVLPs and LVs share the ability to present transmembrane proteins on their surfaces with a multimeric conformation favouring the generation of immune responses. Two envelope proteins have been used in this study. LVs and lentiVLPs were made using a plasmid encoding either the gp160 or the VSV-G envelope or using a combination of these two plasmids resulting in particles pseudotyped with the gp160 envelope protein of HIV-1, the G glycoprotein of the vesicular stomatitis virus or both envelopes, respectively. Indeed, it was previously shown that incorporation of VSV-G into HIV-1 VLPs improved their immunogenicity [17] .
To determine if the particles contained the expected proteins, the different preparations were loaded on a SDS-PAGE gel and western blots were performed using antibodies directed to gp120, VSV-G or p24 Gag capsid protein (Fig. 1) .
All the particles showed the expected gp160 and/or VSV-G envelope proteins. The particles pseudotyped with both gp160 and VSV-G envelope displayed similar amounts of gp120 compared to those made only with the gp160 envelope plasmid alone, but the amounts of VSV-G appeared lower than for the particles pseudotyped with VSV-G only.
We also noticed that the p24 capsid protein was present in preparations of lentiVLPs only if a Rev-encoding plasmid was co-transfected into 293 T cells for their production. One possible explanation is that Rev may be required for particle maturation and Gag processing. Indeed, inability of a monoclonal p24 antibody to bind its cognate epitope when unprocessed Gag is assembled has been demonstrated and attributed to epitope masking [18] . The western blot result was confirmed by an ELISA assay and concentrations of p24 remained undetectable when particles were produced in absence of the Rev-encoding plasmid (Fig. 2) .
The main functions attributed to the Rev proteins of immunodeficiency viruses is the shuttling of viral RNAs containing the Rev responsive element (RRE) from the nucleus to the cytoplasm, mechanistically combined with RNA encapsidation [19, 20] . The Rev-encoding plasmid seemed therefore unnecessary for production of lentiVLPs which do not have to incorporate RNA. However, in accordance with our results, it has been recently suggested that alteration of the Rev function also drastically affects the accumulation of the viral protein p24 [21] .
Quantification of p24 Gag also suggested that, for both LVs and lentiVLPs, higher quantities of p24 Gag were produced when only the VSV-G envelope was used, suggesting a higher number of mature particles.
Study of the lentiVLP size distribution
Particle size has been shown to be crucial for generation of immune responses. As we demonstrated that two types of lentiVLPs could be obtained based on the co-transfection of the Rev plasmid, it was important to determine whether this affected particle size. Diameter of HIV-1 has been estimated between 110 and 250 nm depending on the maturation state and on the technique applied for size determination [22, 23] . Here, size and distribution of the lentiVLPs were determined using dynamic light scattering. We showed that particles had a uniform distribution and a mean diameter ranging from 118 to 148 nm, similar to the size of the HIV-1 virus (Table 2 ). This result was confirmed by electron microscopy of lentiVLPs which showed structured particles with a size around 100-150 nm (Fig. 3) .
Vaccine delivery systems that mimic key features of pathogens have greater chance of being immunogenic. Indeed, the size of antigens is an important factor for their efficient uptake and processing by the immune system and, in contrast to small proteins, pathogen-sized particles and protein aggregates may efficiently be taken up by APCs (for review [3] ). It was also suggested that, by their size alone, virussized particles acted as a new form of pathogen-associated molecular pattern [24] . Particle size can also play a role in antigen transport from the delivery site (mainly muscle or skin) to the lymphoid organs where the immune response is induced. Molecules that are smaller than 10 nm are preferentially reabsorbed into the blood capillaries. Larger particles are favoured for uptake into the lymphatic system, but such uptake is slower. [25] .
Based on their sizes and protein patterns, both lentiVLPs and lentiVLPs-Rev appeared promising for generating immune response directed to gp160. With a view to limit the number of transfected plasmids, lentiVLPs made without Rev were used for the in vivo experiments. Indeed viruses are well known for their ability to adapt through evolution. It appeared therefore critical to design a system able to mimic viral particles in term of physical characteristics while limiting the biological information provided to the cells to avoid recombination events and/or formation of new viruses.
gp160 expression after electrotransfer
Characterization of the gp160 expression levels in the transfected muscles was performed ex vivo by ELISA assay two days after electrotransfer. Surprisingly, we showed significantly higher quantities of gp160 in the transfected muscles when mice were electrotransfered with the envelope plasmid alone compared to a combination of gp160 envelope and packaging plasmids (Fig. 4) . One possible explanation is that particles formed from the cell membranes are released the extracellular media from where they can traffic into lymphatic vessels resulting in lower quantities of gp160 in the transfected muscles. Indeed, Cubas et al. showed that, after injection, VLPs had the capacity to enter the lymphatic vessels and reach the draining lymph nodes while activating antigen-presenting cells in order to initiate the orchestration of signals required for the development of a robust immune response [26] . Consequently, levels of antigen expression at the delivery site could not be correlated to the magnitude of immune response.
In vivo immunization
In order to define the most suitable delivery method for eliciting a potent immune response directed to gp160 envelope, several approaches were studied (Table 3 ). The choice of doses and delivery routes was based on a careful analysis of the literature. It was previously shown that VLPs were able to generate potent immune responses. Different VLP vaccination routes have been studied and it was demonstrated that intradermal immunization might be a preferable route for studies involving VLPs [26] . The VLP doses have also been studied and range between 20 and 100 μg [26] [27] [28] . Concerning DNA vaccines several delivery methods emerged in the past few years and electrotransfer appeared as one of the most efficient. Muscle, tumor and skin were largely studied as target sites for electrotransfer and it was shown that muscles are privileged routes for DNA vaccines resulting in potent cellular and humoral responses [14] . 
Influence of lentiVLP pseudotyping
LentiVLPs pseudotyped with the gp160 envelope or with a combination of gp160 and VSV-G envelopes were injected intradermally. We showed that both types of particles were able to generate antibodies directed to gp160 for all the mice treated and no difference was observed between these two types of lentiVLPs (Fig. 5A) . Previously, it has been demonstrated that pseudotyping of HIV-1 VLPs with VSV-G clearly induced more efficient stimulation of immune responses because the VSV-G proteins mediated antigen entry into dendritic cells through MHC class I and II processing pathways [17, 29] . This effect was lost when fusion-defective mutants of VSV-G were used [17] . The lack of influence of lentiVLP pseudotyping in this study could be explained by (i) the fact that similar quantities of gp160 were present for each type of particle as demonstrated by western blot analyse (Fig. 1) and (ii) lentiVLP preparation was performed without using the Rev plasmid, likely resulting in immature particles with unprocessed Gag. Indeed, Gag processing has been shown to affect envelope-mediated fusion [30] .
Combination of lentiVLPs with Alum adjuvant
Combination of lentiVLP with Alum resulted in more potent immune response, as indicated by the higher gp160 antibody titres (Fig. 5B) . Alum is a commonly used adjuvant and was the first one to be accepted by the FDA for use in humans. Besides a proposed depot-effect leading to slow antigen release, the particulate nature of aluminium salts leads to indirect but specific activation of inflammatory dendritic cells (DCs). Several recent studies have increased our knowledge of the biological events that are induced following Alum administration, in particular on the role of NALP3 inflammasome [31] [32] [33] and on the induction of the danger signal uric acid [34] . Recent findings showed that Alum also bound cell membrane lipids independently on inflammasome and membrane proteins [35] . However several questions remain and the debate on the subsequent induction mechanisms is still open (for review, [36] ). Moreover, its use is associated with some level of cytotoxicity [37] . The development and testing of safer adjuvants and adjuvant free systems is a major area of vaccine research.
DNA vaccine by electrotransfer
Preparation and purification of VLPs is time-consuming and several studies demonstrated that DNA vaccines induced potent immune responses, in particular when combined with certain methods of delivery. The idea behind this experiment was to demonstrate that the plasmids used for preparing lentiVLPs in vitro could be injected directly into the muscle and, combined with electrotransfer, were able to generate a potent immune response against the envelope protein. As previously discussed, we co-delivered only envelope and packaging plasmids, without using Rev, thus limiting the biological information provided to the cells. As expected, an immune response directed to gp160 was shown two weeks after the end of the immunization procedure. Interestingly, the animals immunized with the two plasmids necessary for lentiVLP production developed a much more potent immune response than those immunized with the same quantity of the gp160 envelope plasmid alone (Fig. 5C) . We hypothesised that delivery of lentiVLP encoding plasmids would allow the generation of lentiVLPs in vivo and hence increase the immune responses. Whether lentiVLPs formed in this way are generated and can be detected in vivo and the exact mechanism of their action on the immune system requires further investigation. Alternatively, in vivo co-expression of the genes from the packaging plasmid may have an adjuvant effect, inducing a stronger immune response against gp160. The delivery of a combination three plasmids encoding gp160, VSV-G and packaging proteins resulted in a lower immune response. This suggests that the co-delivery of plasmids knows some limits and that an increased number of plasmids could become difficult to co-transfect. We also observed that the combination of DNA priming and lentiVLP boost resulted in a lower immune response compared to the electrotransfer delivery of the plasmids encoding lentiVLPs for both priming and boost (Fig. 5D) . Several of the recent strategies for HIV immunisation with gp160 have been developed based on heterologous prime-boost vaccines. In these studies, DNA was used for priming and followed by protein [38] , VLPs [39] or virus boosts [40] . Results from these studies were difficult to compare because the number of administrations, doses, time frames and evaluation methods of the efficiency were different but they shared the conclusion that heterologous prime-boost can be more immunogenic than homologous prime-boost. However, there is no clear explanation on the underlying mechanisms [41] . Here, it could be suggested that co-delivery of envelope and packaging plasmids combined the advantages of heterologous vaccines (DNA and lentiVLPs) while injecting only a one-component vaccine.
Electrotransfer offers many advantages for the delivery of vaccines. Firstly, it simplifies vaccine production because the proteins are directly made in vivo by the patients'cells. Second, electrotransfer provokes moderate inflammation at the site of delivery and recruitment of immune cells, a context particularly suitable for the development of antigen responses [42] . Moreover, unmethylated CpG motifs which are carried by the plasmids can activate toll-like receptor 9 (TLR9) signals and act thus as potent adjuvants [43] . Third, muscle electrotransfer results in a prolonged exposure to the antigen; it has been shown that depending on the transgene, encoded proteins could be detected for several months after delivery [44] and that both CD4 and CD8 T cells required sustained antigenic stimulation for maximal expansion [45] . Finally, lentiVLPs generated by in vivo electrotransfer of plasmids potentially offer the potential advantage of presenting the envelope glycoproteins with native trimeric conformation. Indeed, monomeric gp120 has repeatedly failed to induce cross-neutralizing antibodies in clinical trials [46] . The effectiveness of VLPs as presentation and delivery system for conformational proteins was demonstrated with improved neutralization activity [7] .
Qualities of the adaptive response following gp160 immunizations
An effective vaccine against HIV-1 will likely need to induce antibodies that prevent initial infection of host cells or that limit early events of viral dissemination [47] . Even though high antibody titres often correlate with protection against viral disease, the type of response is another crucial parameter. To better define the immune response obtained after gp160 envelope immunization, we determined the relative proportions of the IgG1, IgG2a and IgG2b isotypes. Th2-like immune response is characterized by the production of large amounts of IgG1 but little IgG2a, IgG2b. Th1 cells are involved in the induction of cellular immunity, which is characterized by low or absent antibody production. On the other hand, some Th1-like immune responses are associated with a strong antibody production of the IgG2a, IgG2b subclasses [48] . We therefore examined the type of response by determining the percentage of isotype contributing to the gp160-specific antibody titre (Fig. 6 ). All isotypes were detected after immunization with either VLPs or DNA vaccines, with similar trends for each immunization method and seeming dominance of IgG1. Despite this, possible differences in the sensitivity of each isotypespecific antibody make global conclusions about the Th2 orientation of these responses difficult. Only mice immunized with the combination of gp160 and packaging plasmids appeared to have a lower relative 
Table 3
Immunization and immune response of BALB/c mice. IgG anti-gp160 titres were determined by ELISA two weeks after the boost and mice were defined as responding if their antibody titre was higher than those of all the control mice. ID, intradermal; IM, intramuscular; ET, electrotransfer. level of IgG1 and a higher relative level of IgG2b suggesting a shift towards a Th1 response. We also observed that the IgG2a/IgG2b ratio was superior to 1 when mice were immunized with VLPs only while it was lower to 1 when VLPs were combined with Alum or when DNA vaccines were used.
Conclusions
First, characterisation of lentiVLPs by western blot, dynamic light scattering and electron microscopy has revealed that their protein pattern, size and structure make them promising candidates for HIV-1 vaccines. Although all particles were similar with regard to size and distribution, they clearly differed in p24 capsid protein content suggesting that Rev may be required for particle maturation and Gag processing. In vivo, our study has confirmed that lentivirus-like particles were able to generate antibody responses to gp160 envelope in all the mice treated. The magnitude of the immune response was further enhanced by the use of Alum as adjuvant. We have shown that the plasmids used for producing lentiVLPs in vitro could be delivered directly in vivo by muscle electrotransfer and provoke a potent immune response even if a lower level of gp160 protein was detected at the injection site. In accordance with our hypothesis, the resulting immune response was greater than the one obtained after electrotransfer of the gp160 encoding plasmid alone, suggesting that lentiVLPs may be efficiently produced in vivo or the packaging proteins have an adjuvant effect. In conclusion, lentiVLPs and ET are both efficient delivery methods of gp160 vaccines but the combination of both methods has a synergistic effect. DNA electrotransfer of plasmids encoding lentiVLPs offers many advantages compared to in vitro produced lentiVLPs and appears therefore as a promising delivery method of HIV vaccines.
